A hospital in Hyderabad has opened a new laboratory dedicated to studying the trillions of microbes living in the human gut, with an early focus on inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease. The facility aims to explore whether gut bacteria could one day support new research approaches for people living with these long-term digestive conditions.
Background
IBD causes ongoing inflammation in the digestive tract and can lead to symptoms such as abdominal pain, diarrhoea and fatigue. Researchers have become increasingly interested in the community of bacteria and other microorganisms that live in the gut, often called the gut microbiome. Changes in the balance of these bacteria, sometimes called an imbalance in gut bacteria, have been linked to several digestive conditions, including IBD, although the exact relationship is still being studied.
What Happened
AIG Hospitals in Hyderabad has launched a Gut Microbiome Therapeutics and Pill Lab, according to a report by The Hindu. The hospital said the facility will study the gut microbiome, with an initial focus on IBD.
The laboratory will work on developing capsules containing carefully screened material from donors, intended for use in research settings only. According to the hospital, the process involves several stages, including analysing the donor material, processing and storing samples under controlled conditions, formulating the capsules, and carrying out quality and safety checks before any research use.
AIG Hospitals said the capsules being developed are strictly for research purposes and will only be used as part of approved clinical research studies, not as a general treatment.
Why This Matters
D. Nageshwar Reddy, Chairman of AIG Hospitals, said that supporting a healthier balance of gut bacteria could have potential in long-term inflammatory conditions where standard treatments do not always fully address the underlying biological changes involved. Rupa Banerjee, Director of the hospital’s IBD Centre, said the new laboratory has been designed with an emphasis on scientific quality, donor safety, consistent processes, and traceability. She added that each stage, from screening donors to preparing capsules and monitoring participants, would follow defined research protocols.
For people living with ulcerative colitis or Crohn’s disease, initiatives like this reflect growing scientific interest in the gut microbiome as an area of research, rather than an immediate change to available treatments.
What to Keep in Mind
This announcement describes the opening of a research facility, not the results of a completed study. No findings on safety or effectiveness have yet been reported, and any microbiome-based capsules developed here would need to go through formal research and approval processes before being considered for wider use. People with IBD should continue to follow the treatment plans agreed with their own healthcare team, and should not view this development as an alternative to current medical care.
Reference
AIG Hospitals, Hyderabad. Gut Microbiome Therapeutics and Pill Lab launch announcement, 29 August 2026, as reported by The Hindu Bureau in “Gut microbiome lab launched at Hyderabad hospital to advance research into IBD,” The Hindu, published 29 August 2026. A direct press release or peer-reviewed publication from AIG Hospitals was not available at the time of writing.
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.